School of Medicine
Showing 371-380 of 1,247 Results
-
Bertil Glader
Stanford Medicine Professor of Pediatric Hematology/Oncology, Emeritus
Current Research and Scholarly InterestsHematology/Oncology, biology, and treatment of bone marrow failure disorders, hereditary coagulation disorders-clinical trials.
-
Jeffrey S. Glenn, M.D., Ph.D.
Joseph D. Grant Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsDr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Other interests include exploitation of hepatic stem cells, engineered human liver tissues, liver cancer, and new biodefense antiviral strategies.
-
Anna L Gloyn
Professor of Pediatrics (Endocrinology) and of Genetics
Current Research and Scholarly InterestsAnna's current research projects are focused on the translation of genetic association signals for type 2 diabetes and glycaemic traits into cellular and molecular mechanisms for beta-cell dysfunction and diabetes. Her group uses a variety of complementary approaches, including human genetics, functional genomics, physiology and islet-biology to dissect out the molecular mechanisms driving disease pathogenesis.
-
Neville H. Golden M.D.
Marron and Mary Elizabeth Kendrick Professor of Pediatrics, Emeritus
Current Research and Scholarly InterestsMy research has focused on the medical complications of adolescents with eating disorders. My specific area of study has been the etiology and implications of amenorrhea in adolescents with eating disorders, in particular the management of reduced bone mass and osteoporosis in anorexia nervosa.
-
Shelley Goldman
Associate Dean for Faculty Affairs and for Student Affairs and Professor (Teaching) of Education, Emerita
Current Research and Scholarly InterestsUse and integration of digital technologies for teaching and learning; learning in informal settings, especially learning mathematics and science within families; bringing the tools and mindsets of design thinking to K-12 classrooms and to broadening STEM participation.
-
Andrea Goldstein-Piekarski
Assistant Professor (Research) of Psychiatry and Behavioral Sciences (Sleep Medicine)
BioDr. Goldstein-Piekarski directs the Computational Psychiatry, Neuroscience, and Sleep Laboratory (CoPsyN Sleep Lab) as an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine and PI within the Sierra-Pacific Mental Illness Research, Education and Clinical Center (MIRECC) at the Palo Alto VA. She received her PhD in 2014 at the University of California, Berkeley where she studied the consequences of sleep on emotional brain function. She then completed a Postdoctoral fellowship at Stanford focusing on understanding the brain basis of anxiety and depression.
As the director of the CoPsyN Sleep Lab she is developing a translational, interdisciplinary research program that combines human neuroimaging, high-density EEG sleep recording, and computational modeling to understand the neural mechanisms through which sleep disruption contributes to affective disorders, particularly depression, across the lifespan. The ultimate goals of this research are to (1) develop mechanistically-informed interventions that directly target aspects of sleep and brain function to prevent and treat affective disorders and (2) identify novel biomarkers which can identify which individuals are most likely to experience improved mood following targeted sleep interventions.
This work is currently supported by The KLS Foundation, a R01 from National Institute of Mental Health, and a R61 from the National Institute of Mental Health. -
Natalia Gomez-Ospina
Assistant Professor of Pediatrics (Genetics)
Current Research and Scholarly Interests1. Genome Editing and HSPC-Based Therapeutics
Dr. Gomez-Ospina’s research focuses on developing autologous hematopoietic stem and progenitor cell therapies using CRISPR/Cas9-mediated genome editing. Her work includes targeted integration of therapeutic transgenes into genomic safe-harbor loci, optimization of editing efficiency and safety, and development of transplantation and conditioning strategies that preserve long-term engraftment. A major goal is to create reusable, mutation-agnostic therapeutic platforms that can be adapted across diseases. Her translational work also extends to GMP manufacturing, analytical development, and IND-enabling studies needed to move genome-edited HSPC products toward clinical trials.
2. Neurometabolic and Neurodegenerative Disease Therapeutics
A major area of interest is the development of definitive therapies for lysosomal storage disorders and other neurogenetic diseases, including MPS I, Gaucher disease, Krabbe disease, progranulin deficiency, and Friedreich’s ataxia. Her laboratory investigates how hematopoietic-derived cells can deliver therapeutic proteins to peripheral tissues and the central nervous system. This includes strategies to enhance microglial replacement, improve CNS engraftment, and harness myeloid cells as therapeutic vehicles. The broader objective is to establish cell-based approaches capable of treating both inherited neurometabolic disorders and more common neurodegenerative diseases.
3. Rare Disease Genetics, Functional Genomics, and Lysosome Biology
Dr. Gomez-Ospina also studies the molecular basis of rare and undiagnosed genetic disorders. Through clinical genetics, international collaborations, and the NIH Undiagnosed Diseases Network, her work contributes to novel disease-gene discovery, functional validation of candidate variants, and definition of genotype–phenotype relationships. Her laboratory also investigates lysosomal biology and develops systems-level approaches, including the Lysosome Disease Atlas, to connect lysosome-associated genes with cellular function and human phenotypes. These efforts aim to improve diagnosis while identifying new disease mechanisms and therapeutic opportunities.
For more information go to our website:
https://www.gomezospina.com/
